NOVARTIS AG-SPONSORED ADR (NVS) Stock News
NYSE:NVS - New York Stock Exchange, Inc. - US66987V1098 - ADR - Currency: USD
NVS Latest News, Press Relases and Analysis
Novo Nordisk Moves Amycretin Into Phase 3 Trials For Weight Management, Becomes Europe's Largest Company
Novo Nordisk will begin phase 3 trials for amycretin in early 2026 following promising weight loss data and regulatory discussions.
Novartis' Fabhalta Delivers Hemoglobin Gains, Reduces Fatigue In Patients With Rare Blood Disorder
Novartis' Fabhalta improved hemoglobin, reduced fatigue and eliminated transfusion need in a Phase 3B PNH study presented at the 2025 EHA Congress.
Mentions: AZN
Acquisitions, Licensing Deals Take Centerstage in Pharma/Biotech Space
SNY, BMY, REGN and others ramp up 2025 dealmaking as pharma/biotech giants chase innovation across key growth areas.
1 Warren Buffett Stock That Could Go Parabolic in 2025 and Beyond
This company is just starting to turn around, providing an opportunity for investors.
Novartis (NVS) Could Be a Great Choice
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Novartis (NVS) have what it takes? Let's find out.
Here's How You Can Earn $100 In Passive Income By Investing In Air Products And Chemicals Stock
Air Products and Chemicals Inc. (NYSE:APD) provides atmospheric gases, process and specialty gases, equipment, and related services globally. The 52-week range of Air Products and Chemicals stock price was $243.69 to $341.14. Air Products and ...
Pfizer Signs Experimental Drug Licensing Agreement With 3SBio
Pfizer inks Experimental Drug Licensing Deal With China-based company 3SBio.
Global Billion Dollar Oncology Industry Experiencing Substantial Growth Driven by Increasing Cancer Incidences
Rapt Therapeutics Get A Bullish Recommendation On ‘Significant Opportunity’ For Allergy Drug Candidate: Retail Worries About Cash Position
Clear Street’s initiated with a $3 price target, highlighting RPT904b as a “potentially best-in-class anti-IgE antibody.”
Sanofi to Acquire Blueprint Medicines for up to $9.5 Billion to Expand Immunology Portfolio
Sanofi (SNY) agreed to acquire biopharmaceutical company Blueprint Medicines (BPMC) in a deal worth
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Gilead Reports Positive Data From Trodelvy, Keytruda Combo Study
GILD posts strong phase III results for Trodelvy plus Keytruda, cutting TNBC progression risk by 35% compared with standard care.
Zacks.com featured highlights Novartis, ENGIE, MasTec, Dorman Products and Sterling Infrastructure
NVS, ENGIY, MTZ, DORM, and STRL stand out as low-leverage stocks to help investors weather market volatility with confidence.
How Much Would It Take To Earn $100 A Month From Medtronic Stock
Medtronic (NYSE:MDT) develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. The 52-week range of Medtronic stock price was $75.96 to $96.25. Medtronic's dividend yield is ...
Thoma Bravo considers sale of Apryse for more than $3bn
Apryse has garnered interest from various buyers, particularly other private equity firms.
Mentions: WFC
Buy These 5 Low-Leverage Stocks Amid Volatile Market Sentiment
NVS, ENGIY, MTZ, DORM and STRL offer low leverage and earnings growth, making them safer picks during periods of volatile market sentiment.
Exclusive-Thoma Bravo explores $3 billion-plus sale of software firm Apryse, sources say
(Reuters) -Buyout firm Thoma Bravo is exploring a $3 billion-plus sale of Apryse, after receiving interest from potential buyers of the document processing software provider, people familiar with the matter said on Thursday. Thoma Bravo is working with investment bankers at Lazard on the sale process, said the sources, noting interest had already come from other private equity firms. As part of any deal, Thoma Bravo may decide to retain a minority stake in Apryse, the sources said.
Mentions: WFC
What Makes Novartis AG (NVS) a Differentiated Business?
Loomis Sayles, an investment management company, released its “Global Growth Fund” first quarter 2025 investor letter. A copy of the letter can be downloaded here. In the first quarter, the fund returned -3.35% compared to -1.32% for the MSCI ACWI Net Index. Stock selection in consumer staples, communication services, and healthcare sectors, and allocations to […]
GILD Announces Positive Data on Trodelvy in First-Line Breast Cancer
Gileads Trodelvy shows significant improvement in PFS in phase III ASCENT-03 trial for first-line metastatic TNBC, reinforcing potential as backbone therapy.
Regeneron Initial Data on Multiple Myeloma Drug Encouraging
REGN posts strong early data for linvoseltamab combos in relapsed/refractory multiple myeloma, with ORRs up to 90% and high complete response rates.
Roche Gets FDA Nod for Label Expansion of Susvimo for Third Indication
FDA approves RHHBY's Susvimo for diabetic retinopathy, its third indication, offering 9-month relief with one treatment.
Factbox-The EU's top exports, most vulnerable to Trump's new tariffs
The United States was the trading bloc's biggest export partner in 2024, making up 20.6% of exports, according to Eurostat. Medicinal and pharmaceutical products were the EU's most exported group to the U.S in 2024, followed by motor vehicles and aircrafts and associated equipment, according to the data. The three largest exporters to the United States in the EU were Germany, which exported 161 billion euros ($182.62 billion) worth of goods, Ireland, at 72 billion euros, and Italy, at 65 billion euros.
Mentions: BA
Are You Looking for a High-Growth Dividend Stock?
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Novartis (NVS) have what it takes? Let's find out.
The Smartest Vanguard ETF to Buy With $500 Right Now
Any time is a great time to invest in the Vanguard S&P 500 ETF if you're going to buy and hold for the long term. The best overall pick right now is arguably the Vanguard Utilities ETF. Which is the smartest Vanguard ETF to buy with $500 right now?
The Smartest Vanguard ETF to Buy With $500 Right Now
Incyte Gets FDA Approval for Zynyz in New Cancer Indication
The FDA approves INCY's Zynyz both as monotherapy and in combination with chemotherapy for treating advanced anal cancer.
Here's Why Novartis (NVS) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Novartis (NVS) Upgraded to Buy: What Does It Mean for the Stock?
Novartis (NVS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.